Progenity's Targeted Delivery Of Adalimumab Shows Encouraging Action In Animal Models Induced With Colitis

Progenity Inc PROG has announced results from a preclinical study evaluating the delivery of PGN-001 (adalimumab liquid formulation) drug substance directly to the colon in an animal model of induced colitis.
Adalimumab is the active ingredient used in AbbVie Inc's ABBV flagship rheumatoid arthritis med, Humira.
The study found that adalimumab was detected in tissue along the length of the colon.
Also, a significant reduction in TNF-α, the proinflammatory cytokine target of adalimumab, at every 24 and 48 hours following repeat doses were observed compared with the untreated induced colitis control group.
No treatment-related adverse events were observed, and no measurable adalimumab was detected in the blood.
Progenity's Targeted Therapeutics program consists of drug-device combination products designed to maximize the available dose at the disease site to improve efficacy and potentially reduce systemic toxicity.
The company is currently performing a clinical study to obtain further supporting data for the local delivery of adalimumab, using administration by enema as a surrogate for delivery with the Drug Delivery System (DDS).
Preliminary results are expected in 2021.
Price Action: PROG shares are down 0.41% at $2.41 during the premarket session on the last check Wednesday.